Navigation Links
Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
Date:11/12/2009

tate cancer, and Triolex, in a Phase IIa trial in obese Type 2 diabetes patients. Apoptone and Triolex represent the lead candidates from Hollis-Eden's small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Hollis-Eden please visit www.holliseden.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the presentation of the results of Hollis-Eden Pharmaceuticals, Inc. ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) on November 16; the completion of Hollis-Eden's Phase II trial (HE3286-0401) in obese, insulin-resistant diabetic patients in the first quarter of 2010; the continuation of Hollis-Eden's operations focused on its lead programs into the latter half of 2010; Hollis-Eden's use of data from its ongoing trials to engage with potential corporate partners for the design and funding of late-stage development programs; and Hollis-Eden's ability to conduct proof-of-concept trials in other diseases with an auto-immune inflammatory etiology as resources become available. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hollis-Eden's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within spe
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
2. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
3. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
4. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Viron to Present Data from Phase II Trial at American Heart Association Conference
7. Curemark Presents at Springboard Enterprises Life Sciences Forum
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
9. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
10. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
11. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , ... September 03, 2015 , ... Park Systems ... manufacturing on Sept. 17, 2015 at 9am PST. The webinar will focus on the ... popularly known as 3D printing, additive manufacturing is a broad term that encompasses “addition ...
(Date:9/2/2015)... 2015 Research and Markets ( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of ... special anti-vascular endothelial growth factor agents given by injection into the eye. Dry ... a scientific protocol for the many millions diagnosed with it. AMD usually starts ...
(Date:9/2/2015)... 2015 Biovista Inc. is glad ... 2015 BeHEARD science challenge, a global competition hosted by ... access to the latest life science innovations and technologies. ... pathway analytics capability to support Steven Laffoon ... study of Niemann-Pick Disease Type A (NPA), a rare ...
Breaking Biology Technology:Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2
... prestigious Race Across America the past two years, Team 2CureHD is ... ... Shaffer will begin riding his bike for the third time in as,many years ... that affects his wife and threatens his two daughters., Shaffer and HDSA-San ...
... PLAINS, N.Y., June 10 Provid Pharmaceuticals,Inc. and ... announced the,execution of a research agreement to advance ... Under the arrangement, LLS has contracted with ... of an LLS-funded Specialized Center,of Research (SCOR) grant ...
... for leadership and public service, WASHINGTON, June 10 ... the appointment of Deirdre P. Connelly to,the President,s Commission ... operations for Eli Lilly and Company (NYSE: LLY ... prestigious program for,leadership and public service," Connelly said. "It,s ...
Cached Biology Technology:HDSA-San Diego's Team 2CureHD Continues its Race to Cure Huntington's Disease 2The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia 2The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia 3Lilly's Connelly Appointed to the President's Commission on White House Fellowships 2Lilly's Connelly Appointed to the President's Commission on White House Fellowships 3
(Date:8/31/2015)... August 31, 2015 Growing need ... in government digitization projects to drive India ... published TechSci Research report, " India Biometrics Market Forecast & ... is projected to grow at a CAGR of over ... anticipated on account of extensive use of biometric technology in ...
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
(Date:8/25/2015)... SALT LAKE CITY and BELLEVUE, ... a global leader in advanced robotic systems, announced today ... first-of-its-kind robotic unmanned ground vehicle (UGV), at the National ... Lake City.  The Guardian S is ... is the culmination of years of research and in-field ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... bat species known to visit the flowers of the cardon ... is highly specialized to feed from the flowers, which are ... bat best known for its ability to hear the footsteps ... ground. In a surprising result, scientists at the ...
... understanding of when and how the DNA in developing egg ... new embryo. It is well known that small chemical groups ... modifications to the DNA are acquired during development in the ... in environment. Most of these modifications are removed in immature ...
... Health University Institute, have discovered a new genetic process ... the treatment of neurodevelopmental disorders, such as intellectual disability ... December issue of the American Journal of Human ... Institute researcher, an assistant professor in McGill,s Department of ...
Cached Biology News:Insect-eating bat outperforms nectar specialist as pollinator of cactus flowers 2Insect-eating bat outperforms nectar specialist as pollinator of cactus flowers 3Insight into DNA reprogramming during egg and sperm cell development 2Researchers find new genetic pathway behind neurodevelopmental disorders 2
... Skeletal Myogenesis Kit provides the reagents ... into mature skeletal myotubes. By efficiently ... a valuable tool in studies examining ... developing strategies for muscle cell replacement ...
... Imager delivers high resolution CCD confocal imaging ... effective optical package that fits on your ... combined with high quantum efficiency CCD cameras, ... recording at up to 100 fps. A ...
... Chemicon Select Tissue Arrays are intended for ... tissues were fixed in neutral buffered formalin ... and diagnosis was performed by certified pathologists. ... paraffin blocks and relocated into a new ...
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
Biology Products: